Key Takeaways
- Sharp sequential recovery, but YoY still down: EBITDA margin rebounded from ~8.5% to 11% QoQ as chemical price volatility normalized, though total income and profitability remain below Q1 FY22 levels.
- Non-ibuprofen pharma is now 35–40% of the business, up from ~15% two years ago, but price corrections in metformin and paracetamol compressed margins in that segment this quarter.
- ₹300 crores CAPEX for a new western India plant signals a strategic bet on specialty chemicals and pharma intermediates, with completion targeted within 18 months; land is not yet finalized.
- Management is confident of returning to 15–20% EBITDA margin by year-end, citing falling raw material costs and improving asset utilization, though elevated gas prices remain a concern.
- What to watch next quarter: Whether the non-ibuprofen portfolio stabilizes as raw material costs decline, progress on land acquisition for the new plant, and any update on DMF filings or regulatory approvals that could open regulated export markets.
Financial Performance & Margin Walk
- Chemicals segment turned around sharply: EBIT margin swung from negative 2% in Q4 FY22 to positive 16% in Q1 FY23, driven by normalization of price volatility over the last few months.
- Pharma segment margin compressed sequentially: EBIT margin fell to 23% from 30% in Q4 FY22, though it improved from 12% in Q1 FY22. The decline reflects significant price correction in two key non-ibuprofen products: metformin and paracetamol, with paracetamol falling from ~₹800/kg to below ₹600/kg over two quarters.
- Fenofibrate and clopidogrel continue to perform remarkably well, partially offsetting weakness elsewhere in the non-ibuprofen portfolio.
- Raw material tailwind emerging: Raw material prices have started to come down, which management expects will make non-ibuprofen segment profitability more sustainable going forward. Crude import prices have fallen ~25% from peak, though elevated LNG/CNG prices remain an area of concern.
- Export contribution declined structurally: Exports dropped from 38–39% to 25% of revenue, primarily because international ethyl acetate prices are lower than domestic prices, so the company chose to serve the domestic market; pharmaceutical exports saw no real drop.
Dr. Sanjay Chaturvedi: "So, you know, it's a game of inches actually where we have gone from about 8.5 to 8.7% to 11% in one quarter. So, we do feel confident that by the end of the year, we will be back to between 15 and 20%."
Non-Ibuprofen Pharma Portfolio
- Portfolio share has more than doubled in two years: Non-ibuprofen APIs now represent 35–40% of the total business, up from ~15% two years ago, with an objective of reaching ~50% over the next year to year-and-a-half.
- Ibuprofen expected to decline as a share of API business: Ibuprofen is projected to be about 50% of total API business in the next year or so, down from a higher share today, because ibuprofen will not grow in the same proportion as other businesses.
- Metformin and paracetamol drove the margin hit: Management declined to provide a product-wise breakup of the ~₹130 crores in other APIs, calling it a "very slippery slope" that would lead to further disclosure requests. The real differentiator in metformin, where all manufacturers import DCDA from China, is customer relationships built over decades of ibuprofen supply.
- Profitability improvement requires two levers: Higher asset utilization of products already under commercialization, and a greater percentage of sales from export markets; management expects this may take another couple of quarters.
- DMF filing cadence is accelerating: Three DMFs were filed in the last quarter, with a couple more in the quarter prior; the plan is to file five to six DMFs every year, and as approvals come through, the company will grow into the US market.
Dr. Sanjay Chaturvedi: "If price was the only criteria, then I guess we would all be driving Tata Nano. So, you know, there is some value in long term relationships..."
CAPEX & Strategic Expansion
- New plant is a strategic, not purely financial, call: The ~₹300 crores investment in a new western India plant for specialty chemicals and some pharma intermediates is expected to be complete within 18 months. Land has not yet been bought; two or three options are being evaluated with finalization expected shortly.
- Ethyl acetate capacity expanding 20%: Existing capacity will increase from 100,000 to ~120,000 metric tons per annum, expected on stream by the end of the financial year. Management is "absolutely confident" the market will absorb the additional volume, as the 20,000-ton addition is significantly less than annual market growth.
- Funding mix remains flexible: The ₹300 crores CAPEX will be financed through a combination of internal accruals and, if required, a small level of debt. Management declined to specify a debt-to-equity split, noting it depends on the scale of other planned investments in the next couple of quarters. The balance sheet is strong enough to fund CAPEX without stressing it too much.
- Management views CAPEX timing as a signal of confidence: Steel prices have already fallen 25% in the last two months and crude prices are down, so many input costs have normalized. Even a 30% steel price increase would not proportionally raise project cost, and payback period would change only by a few months.
Dr. Sanjay Chaturvedi: "I think a CAPEX investment in challenging environment, actually is a testament of our confidence and our ability to create value out of the CAPEX that we put in."
Segment Mix & Diversification
- Pharma currently slightly larger than chemicals, but with new CAPEX, chemicals will perhaps outstrip pharma; over a few years, both will be in the 40% to 60% envelope. The mix depends heavily on product pricing, which is more volatile in chemicals: ethyl acetate fell 15% in under two quarters.
- Two new subsidiaries established: IOL Life Sciences and IOL Specialty Chemicals were set up in the last three months. IOL Specialty Chemicals will house the specialty chemicals business; IOL Life Sciences will house API products beyond the current portfolio in a more capital-efficient structure.
- No plans to split the listed entity: Management stated there are no plans at this point to make two different companies out of the chemical and pharma businesses.
- Specialty chemicals EBITDA band set at 6–8%: Management expects this range to hold, with downside slightly below 6% and upside to 8–9%, supported by de-risking through multiple raw material sources across multiple geographies.
Demand Environment & End-Markets
- Ibuprofen demand is stable but slow-growing: World capacity is ~36,000–37,000 tons against demand of 33,000–35,000 tons. Significant growth requires entering newer geographies and getting approvals in regulated markets, which takes years. Capacity utilization is expected to go beyond 75% in the coming few quarters.
- Regulated market demand showing green shoots: After being very soft for over a year due to COVID overstocking, demand from countries with regulatory approvals is reviving; customer visits, conferences, and overseas engagement are resuming with positive signs. Russian and Korean approvals were received last year.
- Rupee depreciation is a tailwind for exports: Management expects better contribution from export markets over the next few quarters as the currency benefit flows through.
- Domestic economy providing support: Strong revival in consumption and services sector recovery, aided by a lower base last year due to the COVID second wave.
Dr. Sanjay Chaturvedi: "So, you clearly understand this game Gautam that to get approvals in regulated markets is not a question of months and quarters. It's a question of years and this is a journey we started several years ago."
Regulatory & Product Pipeline
- US FDA audit status is clean but dated: The last US FDA audit was in October 2019; no audits are currently pending.
- Three pending DMFs were queried but not updated: Management declined to provide a status update, stating they do not have approval yet and will announce when they get approved. [13–14]
- New API commercialization timeline is deliberately vague: When asked whether products like Apixaban are entering production in upcoming quarters, management deflected, saying it is premature to speculate on products under development until filings are done, batches are taken, and products are qualified with customers. [14–15]
- Focus in the immediate quarter is execution, not pipeline speculation: The priority is improving asset utilization of products already under commercialization.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin recovery | Return to 15–20% EBITDA margin | By end of FY23 |
| New plant CAPEX completion | ₹300 crores investment in western India plant | Within 18 months |
| Ethyl acetate capacity expansion | Increase from 100,000 to ~120,000 metric tons per annum | By end of FY23 |
| Non-ibuprofen pharma share | Reach ~50% of pharma segment | Within next year to year-and-a-half |
| Ibuprofen share of API business | Decline to ~50% of total API business | Within next year or so |
| DMF filing cadence | File five to six DMFs every year | Ongoing, annually |
| Ibuprofen capacity utilization | Move beyond 75% utilization | Coming few quarters |
| Non-ibuprofen profitability improvement | Higher asset utilization and greater export share | Another couple of quarters |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Total income | ₹570 cr, vs ₹524 cr in Q1 FY22 and ₹579 cr in Q4 FY22 |
| EBITDA | ₹61 cr, vs ₹116 cr in Q1 FY22 and ₹50 cr in Q4 FY22 |
| EBITDA margin | 10.7%, vs 8.6% in Q4 FY22 |
| Net profit | ₹34.9 cr, vs ₹67 cr in Q1 FY22 and ₹27.8 cr in Q4 FY22 |
| Chemicals segment EBIT margin | 16%, vs 5% in Q1 FY22 and negative 2% in Q4 FY22 |
| Pharma segment EBIT margin | 23%, vs 12% in Q1 FY22 and 30% in Q4 FY22 |
| Cash and cash equivalents | ~₹300 cr as of June 30, 2022 |
| Short-term debt | ~₹400 cr; no long-term debt on books |
| Planned CAPEX for new plant | ~₹300 cr, to be funded primarily through internal accruals with possible small debt |
| Ibuprofen capacity utilization | 70–75% |
| Ibuprofen pricing | $11–$12 per kilo |
| Ibuprofen volume | ~800 tons per month |
| Ibuprofen capacity market share (India) | 33–35%; sales-wise market share ~30% |
| Non-ibuprofen share of total business | 35–40%, up from ~15% two years ago; target ~50% in next year to year and a half |
| Export contribution to overall sales | 25%, down from 38–39% previously, driven by chemicals segment where international ethyl acetate prices are lower than domestic |
| Ethyl acetate capacity | 100,000 metric tons per annum; expansion to 120,000 MT by end of FY23 (20% increase) |
| Ethyl acetate pricing change | Down ~15% in Q1 FY23 vs Q4 FY22 |
| DMFs filed in Q1 FY23 | 3; plan to file 5–6 DMFs every year |